Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

VFC's Stock House: Synergy Pharmaceuticals (SGYP) Ready To Roll

(EMAILWIRE.COM, May 22, 2012 ) New York, NY -- VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, reported today that Synergy Pharmaceuticals (SGYP) may be in a position to realize significant share price gains over the coming months.



Synergy Pharmaceuticals (SGYP) ran to over seven dollars last month on increasing volume as the company's billion dollar potential took shape and numerous analysts jumped on board with encouraging write-ups and bold price predictions.



Synergy also received a boost when its chief competitor, Ironwood Pharmaceuticals (IRWD) received a setback at the FDA that allows SGYP an extra three months to play catch up in the race to commercialization for each company's respective product candidate, both of which target the same indication. Synergy's product Plecanatide, however, has a much more favorable side effect profile, making the Ironwood setback that much more of a key factor when discussing future market potential.



Both products, Synergy's Plecanatide and Ironwood's Linaclotide, are being developed to treat chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C). Linaclotide is already before the FDA for review, although the review was delayed by three months, as mentioned before, while Phase II/III Plecanatide results are due out later this year.



The head start to market may provide Ironwood with a distinct advantage, but the advantage might not last too long when Plecanatide shows up on the scene.



During the Linaclotide trials, the drug was successful in alleviating symptoms relating to IBS-C and CIC when compared to a placebo, but the kicker is that patients experienced side effects that included cases of extreme diarrhea, essentially reversing the symptom being treated. Some cases of diarrhea were so bad that 6% of the patients decided to abandon the trial altogether.



On the open market - with a competing product out there for which there have been no such cases noted - that means those patients would likely switch to the alternative, in this case Plecanatide, that is not associated with carrying around a roll of Charmin' Soft at all times.



For full report visit: http://vfcsstockhouse.com/blog/article/-synergy-pharmaceuticals-sgyp-may-be-ready-to-roll



For full report and opinion visit: http://vfcsstockhouse.com/blog/article/-the-facebook-fb-ipo-don-t-believe-the-hype



Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse



'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213



About VFCsStockHouse.com:



VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFCs Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.



For full disclaimer visit: http://vfcsstockhouse.com







VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News
Health News Headlines - Yahoo News
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on top health stories.

Pfizer's Ibrance drug slows progression of breast cancer
30 May 2015 at 10:17am
By Deena Beasley CHICAGO (Reuters) - A Phase III trial of Pfizer Inc's Ibrance showed that, in combination with hormone therapy, the drug more than doubled the duration of disease control for women with the most common type of breast cancer. At the time of an interim analysis, patients given Ibrance and AstraZeneca Plc's Faslodex (fulvestrant), a widely used treatment to block estrogen, lived an average of 9.2 months before their cancer worsened. The trial, presented in Chicago at a meeting of the American Society of Clinical Oncology, enrolled 521 patients whose breast cancer was classified as estrogen-receptor positive, human epidermal growth factor receptor 2-negative.

Study sees benefit from more extensive breast cancer surgery
30 May 2015 at 9:54am
CHICAGO (AP) ? Having a little extra tissue taken off during breast cancer surgery greatly lowers the risk that some cancer will be left behind and require a second operation, according to a new study that could change care for more than 100,000 women in the United States alone each year.


New treatments may prolong health after breast cancer
30 May 2015 at 8:59am

Promising advances in research could mean longer, healthier lives for women with breast cancer, the number one cancer in women worldwide, experts said Saturday at a major US cancer conference. A new targeted therapy that appears to double the amount of time cancer can be held in check, a drug that offers more women a chance at healthy lives post-diagnosis and a surgical option to remove extra tissue in order to reduce the likelihood of cancer's return were among the findings presented at the American Society of Clinical Oncology annual meeting in Chicago. The targeted drug, palbociclib, is made by Pfizer and was granted accelerated approval by the US Food and Drug Administration earlier this year for use in women with the most common form of advanced breast cancer, known as estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-).



4 Traps to Avoid When You're Filled With Anxiety
30 May 2015 at 8:57am

When we're slipping on anxiety's slopes, it's usually not pretty.We rant. We rave. We make blanket statements on the condition of our lives.When under pressure, inaccurate self-judgments are likely to creep in. We forget to factor in that we're overworked, tired or just plain depleted. We lose sight that we're resilient, and quite capable of...



Former quadriplegic runs, walks to show others they can
30 May 2015 at 8:46am

LOS ANGELES (AP) ? The worst day of Aaron Baker's life wasn't when the then-20-year-old professional motocross racer crashed his bike one spring day in 1999, flew over the handlebars and hit the ground head-first, paralyzing him from the next down.


Eisai drug extends survival in patients with rare cancers
30 May 2015 at 8:05am
A drug made by Japan's Eisai Co that was originally derived from sea sponges helped extend lives of patients with soft-tissue cancers known as sarcomas by two months, a significant advance for these rare cancers with few treatment options, Belgian researchers said on Saturday. The researchers studied the drug, known as eribulin, in 452 patients with two forms of sarcomas - leiomyosarcoma, which starts in smooth muscles, and adipocytic sarcoma, which starts in fat tissue. "For a disease where such few treatment options exist, a two month improvement in survival is significant," said Dr. Patrick Schoffski, a medical oncologist at University Hospitals Leuven in Belgium, who presented the findings at the American Society of Clinical Oncology meeting on Saturday.

J&J multiple myeloma drug offers hope after others stop working: study
30 May 2015 at 8:03am
An experimental biotech drug being developed by Johnson & Johnson may offer hope to multiple myeloma patients who have run out of options, according to data from a midstage study released at a cancer meeting on Saturday. J&J plans to use the Phase II study to seek U.S. and European approval of its antibody daratumumab to treat the blood cancer. The drug received breakthrough designation from the U.S. Food and Drug Administration, which can help speed the approval process.


New research shows immunotherapy targeting several cancers
30 May 2015 at 7:38am

Immunotherapy, which has shown remarkable success against advanced melanoma skin cancers, is now being used to target other cancers that are tough to treat. The results of several clinical trials were presented on the opening day of the American Society of Clinical Oncology's (ASCO) annual conference in Chicago on Friday. In some cases, immunotherapy has been shown to completely eradicate cancer.



Drug boosts long-term survival after breast cancer: study
30 May 2015 at 7:24am

After a diagnosis of localized breast cancer, women are often prescribed tamoxifen for five years to help prevent a recurrence, but researchers said Saturday another drug, anastrazole, may work better. The federally funded phase III study involved more than 3,100 postmenopausal women with a kind of breast cancer known as ductal carcinoma in situ, which was treated by removing the cancerous lump followed by a radiation regimen. Some women were then randomly assigned to receive tamoxifen and others anastrazole.



U.N. warns of coming hunger in North Korea
30 May 2015 at 2:58am

By Tom Miles GENEVA (Reuters) - A drought in North Korea could lead to huge food shortages this year, the top U.N. official in the country told Reuters in an interview. Rainfall in 2014, the lowest in records going back 30 years, was 40-60 percent below 2013 levels, and reservoirs are very low, said Ghulam Isaczai, the U.N. resident coordinator.



U.S. military orders review as anthrax mishap widens
29 May 2015 at 10:31pm

By Phil Stewart WASHINGTON (Reuters) - The U.S. military said on Friday it discovered even more suspected shipments of live anthrax than previously thought, both in the United States and abroad, and ordered a sweeping review of practices meant to inactivate the bacteria. The Pentagon said a total of 11 states, two more than it first acknowledged, received "suspect samples," as did Australia and South Korea. It had previously only identified a foreign shipment to a U.S. air base south of Seoul.


Rights activists protest award for ex-Montana judge who blamed victim of rape
29 May 2015 at 8:07pm
A small group of women's rights activists rallied in Montana on Friday to protest a lifetime achievement award for a state judge censured for suggesting that a 14-year-old girl was partly to blame for her rape by a teacher. More than two dozen protesters led by the Montana chapter of the National Organization for Women attended the candlelight vigil outside the Yellowstone Art Museum in Billings where former state District Judge G. Todd Baugh was to be given the annual award by a local bar association, said Marian Bradley, regional NOW head.

Kansas hospital monitoring patient for possible Ebola infection
29 May 2015 at 5:43pm
The University of Kansas Hospital said on Friday it was monitoring a patient for a possible Ebola infection after he returned from the West African nation of Sierra Leone and developed a fever. "The patient is extremely low risk. It's just the fever that tipped the balance," Dr. Lee Norman at University of Kansas Hospital in Kansas City, Kansas, told a news conference.


Pentagon: Anthrax shipments broader than first thought
29 May 2015 at 4:07pm

WASHINGTON (AP) ? The Pentagon said Friday that the Army's mistaken shipments of live anthrax to research laboratories were more widespread than it initially reported, prompting the Defense Department's second-ranking official to order a thorough review.


U.S. military orders broad review as anthrax mishap widens
29 May 2015 at 3:39pm
WASHINGTON (Reuters) - The U.S. military said on Friday it discovered even more suspected cases of inadvertent shipments of live anthrax than previously thought, both in the United States and abroad, and ordered a sweeping review of its practices for inactivating samples. "As of now, 24 laboratories in 11 states and two foreign countries are believed to have received suspect samples," the Pentagon said in a statement. (Reporting by Phil Stewart; Editing by Sandra Maler)

Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC